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Abstract
This study investigated the effect of systemic salicylate on central auditory and non-auditory
structures in mice. Since cochlear hair cells are known to be one major target of salicylate,
cochlear effects were reduced by using kanamycin to remove or impair hair cells. Neuronal
brain activity was measured using the non-invasive manganese-enhanced magnetic reso-
nance imaging technique. For all brain structures investigated, calcium-related neuronal
activity was increased following systemic application of a sodium salicylate solution: proba-
bly due to neuronal hyperactivity. In addition, it was shown that the central effect of salicy-
late was not limited to the auditory system. A general alteration of calcium-related activity
was indicated by an increase in manganese accumulation in the preoptic area of the ante-
rior hypothalamus, as well as in the amygdala. The present data suggest that salicylate-
induced activity changes in the auditory system differ from those shown in studies of noise
trauma. Since salicylate action is reversible, central pharmacological effects of salicylate
compared to those of (permanent) noise-induced hearing impairment and tinnitus might
induce different pathophysiologies. These should therefore, be treated as different causes
with the same symptoms.
Introduction
Salicylate is known to induce reversible loss of auditory sensitivity and tinnitus both in humans
[1–8] and animals [9–16]. Therefore, the substance has been used in several animal studies that
aimed to investigate the generation of tinnitus. Previous in-vivo and in-vitro studies have
shown that acute application of sodium salicylate causes changes of outer (OHC) and inner
(IHC) hair cell function, as well as an altered activity in central auditory and non-auditory
structures. In the inner ear (the cochlea), salicylate leads to both functional and structural
changes. Salicylate markedly reduces the cochlear blood flow by vasoconstriction [17]. Further-
more, changes in IHC synaptic morphology occur [18] with hair cell resting potential modified
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through a reduction in outward potassium currents [19, 20]. This blocks IHC function, leading
in turn to a decreased neurotransmission. In OHCs, vasoconstriction leads to an impaired elec-
tro-motility by reducing the lateral wall stiffness [21] and the amount of electro-motile length
changes [22–24]. A partial loss of cochlear amplification with its down-regulation of cochlear
output is reflected by decreased DPOAE- and CAP-amplitudes. Salicylate action on cochlear
NMDA receptors might be partly responsible for peripheral tinnitus generation [13, 25–27].
Beside these cochlear changes, salicylate also modulates neuronal activity in the central
auditory pathway in a dose-dependent manner. It has been demonstrated that changes in
cochlear output leads to an altered spontaneous activity in the auditory nerve. Whereby salicy-
late studies in cats revealed an increase in nerve fibre activity, spontaneous discharge rates were
shown to decrease in gerbils [28, 29, 30]. Histological studies have shown that salicylate
increases c-fos expression in the dorsal cochlear nucleus (DCN), inferior colliculus (IC), medial
geniculate body (MGB) and auditory cortex (AC) [31, 32]. However, an elevation was also
observed in several non-auditory structures in the brainstem, thalamus or amygdala [31, 33].
Furthermore, an enhanced activation of neural tissue has been shown in the ventral cochlear
nucleus (VCN), indicated by an increased neuronal nitric oxide synthase (nNos)-expression in
principal neurons [34]. Salicylate also causes increased activity in serotonergic neurons, accom-
panied by an altered synaptic function, resulting in a downregulation of GABA and an increase
in glutamate activity in tinnitus-related auditory brain structures [9, 35–40]. An upregulation
of the genes Arc/Arg3.1 and Egr-1, as well as the NMDA receptor subunit 2B (NR2B) in the
dorsal cochlear nucleus, indicates a strengthening of central excitatory synaptic connections
due to salicylate application [41]. The changes observed in neurotransmission may induce
sound-evoked hyperactivity due to an increase in excitatory projections [42–44], particularly
affecting the thalamo-cortical system during tinnitus generation [27, 45]. Further, it has been
shown that cochlear output and AC tonotopy are shifted towards tinnitus-associated frequen-
cies [46].
Beside these findings, several previous studies have investigated the effects of systemic salic-
ylate application with regard to the modulation of spontaneous or evoked activity in central
auditory structures. In summary, the results demonstrated that the majority of neurons change
their spontaneous activity upon salicylate application. An increase was observed in the fre-
quency range showing tinnitus-related behaviour, whereby neurons with low spontaneous fir-
ing rates were particularly affected, even in the auditory cortex. In contrast, a salicylate-
induced reduction in multi-unit activity was also detected in awake animals (e.g.: IC–[47–49];
AC–[27, 44, 50, 51]). Moreover, spontaneous calcium-dependent activity, after systemic salicy-
late application, was significantly increased at the level of the dorsal cochlear nucleus (DCN)
and inferior colliculus (IC) [52]. When measuring evoked neuronal responses after salicylate
treatment, a depression of cochlear potentials has been observed, whereby local field potentials
were increased in central nervous system structures, including medial geniculate body, auditory
cortex and lateral amygdala [53].
These changes of central neural activity could be caused by the peripheral or the central
effects of salicylate. Recordings in brain slices showed a direct, dose-dependent pharmacologi-
cal action of salicylate on several central auditory and non-auditory structures [54, 55]. How-
ever, little is known about the impact of central and peripheral effects of salicylate application
on the generation of salicylate-induced tinnitus.
Using manganese-enhanced magnetic resonance imaging (MEMRI), the present study
investigated the effect of systemic salicylate application on calcium-related activity in central
auditory structures after reducing the peripheral effects mediated by cochlear hair cells as one
major target of salicylate action.
Salicylate-Induced Changes in Brain Activity
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Materials and Methods
Animals
In the present study, 30 normal hearing adult (postnatal 30–60 day) mice (Mus musculus,
NMRI strain) of both sex were examined. Different animals were used for threshold testing
and MEMRI measurements. The experimental protocol was approved by the governmental
commission for animal studies (LaGeSo Berlin, approval number: G 0153/06). Experiments
were carried out in accordance with the EU Directive 2010/63/EU on the protection of animals
used for scientific purposes. All efforts were made to minimize the number of animals and
their suffering. The condition of animals was monitored every 6 hours after the induction of
hearing loss and, in addition, every hour following substance injection (kanamycin, salicylate
or manganese, respectively). Since animals did not show any abnormal behaviour, additional
analgesic treatment was not necessary.
Experimental induction of kanamycin-induced hair cell damage
For 22 mice, cochlear tissue was damaged by a subcutaneous injection of kanamycin sulfate
(Carl Roth, Karlsruhe, Germany) dissolved in phosphate-buffered saline (PBS), at 1 mg/g body
weight followed 40 minutes later by an intraperitoneal injection of bumetanide (Sigma-Aldrich,
St. Louis, MO, USA) at 0.05 mg/g body weight. This procedure has been shown to elicit a sig-
nificant and rapid hair cell loss in mice in-vivo [56]. Three of the above treatments were admin-
istered, each separated by 48 hours, to ensure a profound loss of sensory outer and, to a lesser
extent, inner hair cells. Following kanamycin and bumetanide treatment, 7 animals underwent
ABR recordings while 15 mice were used for MEMRI measurements.
ABRmeasurements
Auditory thresholds were measured for 7 hearing-impaired mice (48 hours after the final injec-
tion) and for 8 normal hearing control mice. Different animals were used for each group. The
time interval for deaf mice was chosen to avoid any additional central pathophysiological
effects arising from the damaged peripheral auditory system.
Frequency-specific (4, 8, 12, 16 & 20 kHz) auditory brainstem responses (ABR) were
recorded under anaesthesia. Sub-dermal needle electrodes were placed at the vertex (active),
mastoid (reference) and at one foot (ground). Tone stimuli were delivered binaurally at differ-
ent SPLs with a sine-wave generator (Modell SSU2, Werk für Fernmeldewesen, Berlin, Ger-
many). ABR recordings were carried out using a Viking IV1measurement system (Viasys
Healthcare, Conshohocken, Pennsylvania, USA). The brainstem responses (recording epoch
10 ms following stimulus presentation) were amplified (100.000 x), filtered (bandwidth 0.15–3
kHz) and averaged (300 x) by the Viking IV1. The amplitude growth function of wave IV/V
was calculated from the resulting data for each frequency tested and a linear regression was fit-
ted to the function. By extrapolating the regression line to zero, mean auditory thresholds were
estimated for the controls and the kanamycin-treated animals. Results are shown as mean audi-
tory thresholds (± S.E.) in dB SPL by group and mean relative hearing loss of the treated group
compared to the normal hearing controls.
Salicylate application
To investigate salicylate-induced changes in central calcium-dependent activity after kanamy-
cin-induced damage of cochlear hair cells, 9 treated animals received an intraperitoneal (i.p.)
injection of a sodium salicylate (SS) solution (250 mg/kg). It has been shown earlier that salicy-
late is able to cross the blood brain barrier shortly after systemic (e.g. i.p.) application leading
Salicylate-Induced Changes in Brain Activity
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to an increased cerebrospinal fluid level of salicylate [57–59]. Comparable SS concentrations
were also used in former studies to elicit salicylate-induced tinnitus in rodents [13, 60, 61]. SS
was injected 48 hours after the last kanamycin/bumetanide treatment.
Manganese-enhanced magnetic resonance imaging (MEMRI)
MEMRI is a powerful tool to image central nervous system activity in small animals in-vivo
[62–64]. After systemic application of a manganese chloride solution, manganese ions cross
the blood-brain barrier [65] and enter excited cells by substituting calcium influx during neu-
ronal activity [64, 66, 67]. Due to a slow clearance, Mn2+ accumulates within the tissue which
results in an increase in MRI-T1 signal contrast and therefore reflects the Ca2+-dependent
activity [68]. Thereby, neuronal activity is monitored using the MEMRI technique and, thus,
Ca2+-dependent activity can be imaged. This provides an opportunity to integrate neuronal
activity, represented by the increase in signal contrast due to manganese accumulation, over a
well-defined period of time before measurements, i.e., 24 hours in the present experiments.
This is of particular importance during the investigation of auditory-related activity even inside
a noisy MRI scanner [52, 69–71].
On the day of the experiments and 48 hours after the final kanamycin/bumetanide treat-
ment (i.e. immediately after SS injection in the salicylate group), animals of the experimental
group (treated with kanamycin/bumetanide and salicylate) as well as hearing-impaired control
mice (kanamycin/bumetanide-treated only) received a 0.4 mM/kg dose of MnCl2 solution (in
accordance with [71]). Delivery was via a single intraperitoneal injection. Twenty-four hours
after the manganese treatment (prior to this animals were kept in their cages in a quiet environ-
ment), when manganese accumulation reached its maximum level in the relevant brain struc-
tures [72], MRI scanning was performed. During MRI scanning, anaesthetised mice were
placed on a heated circulating water blanket to ensure constant body temperature of 37°C.
Anaesthesia was induced with 3% and maintained with 1.5–2.0% isoflurane (Forene, Abbot,
Wiesbaden, Germany) delivered at 0.5 l ⁄ min of 100% O2 via a facemask under constant venti-
lation monitoring (Small Animal Monitoring & Gating System, SA Instruments, Stony Brook,
New York, USA). Animals were euthanized after MRI measurements by an overdose of isoflur-
ane (>5% isoflurane at 0.5 l/min of 100% O2).
Manganese-enhanced MRI was carried out using a 7 Tesla rodent scanner (Pharmascan 70 /
16AS, Bruker BioSpin, Ettlingen, Germany) with a 16 cm horizontal bore magnet and a 9 cm
(inner diameter) shielded gradient with a H-resonance-frequency of 300 MHz and a maximum
gradient strength of 300 mT/m. For imaging a 1H-RF quadrature-volume resonator with an
inner diameter of 20 mm and a T1-weighted 2D turbo spin-echo sequence (TR / TE = 938 /
10.6 ms, RARE factor 2, 6 averages) was used. Data acquisition and image processing were con-
ducted using the Bruker Paravision 4.0 software. Thirty-five axial slices with a slice thickness of
0.3 mm, a field of view of 2.85 x 2.85 cm and a matrix of 256 x 256 resulted in an in-plane reso-
lution of 111μm. Imaging covered the brain from brainstem to forebrain. Signal intensity anal-
ysis of defined auditory brain regions was carried out with the program Analyze 5.0
(AnalyzeDirect, Inc.; Lenexa USA). Signal intensities were quantified bilaterally in the dorsal
(DCN) and ventral (VCN) cochlear nucleus, the superior olivary complex (SOC), the inferior
colliculus (IC), the medial geniculate body (MGB), the auditory cortex (AC), the preoptic area
of the anterior hypothalamus (PO/AH), the Amygdala (Amyg). The masseter muscle was used
as an objective intensity reference, since it is located close to the related neural tissue but is not
affected by changes in brain activity. PO/AH and Amyg served as non-auditory structures
investigated in the present study. Regions of interest were marked in accordance with “the
mouse brain atlas in stereotaxic coordinates” [73] (Fig 1). The investigated brain structures
Salicylate-Induced Changes in Brain Activity
PLOS ONE | DOI:10.1371/journal.pone.0153386 April 14, 2016 4 / 14
were manually outlined within each relevant brain slice and a voxel-based analysis was carried
out for each structure under observation. Due to variations in each animal’s position within the
MRI scanner, the dimensions of each brain structure (the tissue volume) in the scan could vary
across subjects. Therefore, the number of voxels included in each structure differs slightly. Sig-
nal intensities for all analysed structures were normalized in relation to the intensity of the
muscle at the same side. The relative MRI signal (given in normalized relative units) was calcu-
lated for each animal by using the mean of the measured signal strength of every slice for each
analysed structure, normalized in relation to the intensity for the muscle at that side. The
results of all animals were compared between the salicylate group and the hearing-impaired
control group for each investigated brain area.
Statistical analysis
The statistical comparison was done with the software SPSS (IBM SPSS Statistics Version 20,
IBM Corp., Armonk, New York, USA). After confirming a normal distribution using the Kol-
mogoroff-Smirnoff-test, the t-test for independent samples was applied. A statistically signifi-
cant difference was considered for p<0.05.
Results
ABR-recordings
Hearing loss following kanamycin and bumetanide treatment was indicated by an ABR-thresh-
old shift of up to 40 dB in the investigated frequency range between 4 and 20 kHz compared to
the untreated normal hearing control group. Frequency-dependent mean auditory thresholds
in normal hearing controls ranged between 17 and 31 dB SPL. In the hearing impaired animals,
thresholds were detected between 53 and 60 dB SPL (Fig 2). Average hearing loss in the
Fig 1. Examples of MEMRI-images of a mouse brain with labelled regions of interest.Outlines show the auditory structures of: a) the dorsal and ventral
cochlear nucleus (CN), b) the superior olivary complex (SOC), c) the inferior colliculus (IC), d) the medial geniculate body (MGB) and primary auditory cortex
(AC). Further, the non-auditory structures of e) the amygdala (Amyg) as well as f) the preoptic area of the anterior hypothalamus (PO/AH) are indicated in the
images. Masseter muscle (M) is indicated in image a) on the CN level, used for normalization of image brightness within each slice. (Images were taken from
a preliminary study to establish the MEMRI method performed on untreated animals).
doi:10.1371/journal.pone.0153386.g001
Salicylate-Induced Changes in Brain Activity
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experimental group ranged between 26 dB at 4 kHz and 40 dB at 16 kHz. However, threshold
shift was highly significant for all frequencies (p<0.001).
MEMRI
Following systemic salicylate application, MEMRI contrast increased significantly in all investi-
gated auditory brain areas.
In detail, the relative MRI signal intensities were raised in the DCN from 128.0±2.8 in hear-
ing-impaired controls to 152.9±1.9 in the hearing-impaired salicylate group and for the VCN
from 127.2±2.4 (hearing-impaired controls) to 151.2±1.9 (salicylate group). In the SOC, the
signal increased from 133.1±2.0 (in hearing-impaired controls) to 149.2±1.8 in salicylate-
treated animals. Similar observations have been made in the IC (hearing-impaired controls:
128.0±2.2; salicylate group: 138.2±1.9), in the MGB (hearing-impaired controls: 132.1±1.9;
salicylate group: 143.6±1.5) as well as in the AC (hearing-impaired controls: 130.0±1.1; salicy-
late group: 141.7±1.4) (Fig 3).
An increased MEMRI signal was also observed for the non-auditory control areas (PO/AH
and Amyg) after salicylate treatment. Signal intensities were elevated from 148.5±2.0
Fig 2. Auditory thresholds before and after damage of the auditory periphery.Hearing thresholds (mean±S.E.) in mice 48 hours after a threefold
injection (applied every 48 hours) of kanamycin (1 mg/g body weight) and bumetanide (0.05 mg/g body weight) (kanamycin-treated group, n = 7) in relation to
normal hearing control animals (normal hearing group, n = 8). Graph further indicates the mean threshold shift of the experimental group. Asterisks point to
significant differences between normal hearing and hearing impaired animals for all investigated frequencies between 4 and 20 kHz (p<0.001).
doi:10.1371/journal.pone.0153386.g002
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(hearing-impaired controls) to 175.0±2.1 (salicylate group) in PO/AH and from 143.6±3.0 in
hearing-impaired controls to 167.8±2.5 in salicylate-treated animals in the amygdala region
(Fig 3). All data are given in normalized relative units (calculated from the measured signal
intensities, as described in the methods section) as mean ± S.E.
The differences between the groups were statistically significant for all investigated auditory
and non-auditory structures (p0.001 for all comparisons).
Discussion
The results of the present study demonstrate changes in calcium-dependent brain activity after
systemic salicylate application in kanamycin-treated animals using non-invasive manganese-
enhanced magnetic resonance imaging (MEMRI).
ABR thresholds
The ABR recordings demonstrated that a three-fold application of kanamycin and bumetanide
produces a significant threshold shift in mice, possibly in particular due to OHC destruction
according to previous reports. It is further assumed that the treatment induces a minor loss of
IHC and spiral ganglion cells as well [56, 74]. Although it has not been directly investigated
here, such a decrease of sensory cells is supported by the electrophysiological findings pre-
sented here. The hearing loss after kanamycin and bumetanide treatment of up to 40 dB
matches to the results of other studies showing that a near-complete loss of OHC function in
mice results in a comparable shift of auditory thresholds [26]. These findings lead to the
assumption that the observed central effects of salicylate are only marginally related to its
Fig 3. Mean MEMRI contrast of experimental groups. Relative manganese-enhanced MRI-T1-contrast (mean±S.E.) for the investigated auditory and non-
auditory brain structures in hearing-impaired control (black columns) compared to salicylate-treated (white columns) mice. Both groups had a profound
hearing loss due to peripheral damage by kanamycin/bumetanide treatment before experiments. Asterisks indicate significant differences between the
groups (p<0.05). Investigated structures: dorsal cochlear nucleus (DCN), ventral cochlear nucleus (VCN), superior olivary complex (SOC), inferior colliculus
(IC), medial geniculate body (MGB), auditory cortex (AC), preoptic area of the anterior hypothalamus (PO/AH), Amygdala (Amyg).
doi:10.1371/journal.pone.0153386.g003
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action on outer hair cells. Inner hair cells might also be affected which could further contribute
to our results.
Ca2+-related effect of salicylate after peripheral hearing impairment
Recent studies have reported that the central auditory system largely contributes to the salicy-
late-induced effects on neuronal activity and auditory phantom perceptions like tinnitus, even
after disconnection of the auditory periphery [54, 75, 76]. In the present data, the calcium-
related neuronal activity was increased after systemic application of a sodium salicylate solu-
tion in several investigated brain structures. This followed kanamycin-induced reduction of the
peripheral input from cochlear sensory cells. In addition, it was shown that the central effect of
salicylate is not limited to the auditory system, but shows a rather general alteration of cal-
cium-related activity, as indicated by the increased manganese accumulation in the preoptic
area of the anterior hypothalamus (PO/AH) as well as in the amygdala. Basta et al. [55] showed
an increased spontaneous activity during salicylate superfusion in brain slices of auditory and
non-auditory (hypothalamic) structures. The hypothalamus is a central structure responsible
for thermoregulation, which maintains the body temperature at a constant level. When salicy-
late is given in patients with elevated temperature (fever), it exerts an antipyretic effect. In rats,
the intra-ventricular application of salicylate close to the PO/AH can induce hypothermia [77],
which might be related to an altered neuronal activity in the corresponding structure as shown
in the data (body temperature was kept constant during MRI scanning only). This additional
activity increase, despite the overall changes in neural tissue, could also provide an explanation
for the higher salicylate-induced effect in the hypothalamus and amygdala compared to the
auditory system. Further support comes from earlier findings that systemic application of salic-
ylate leads to a strong decline in body temperature [78].
An altered activity of the amygdala after salicylate application has already been reported by
immunostaining. An elevated c-Fos- or arg3.1-related activity was demonstrated in the audi-
tory cortex and the amygdala after treatment with a single high-dose salicylate application
[33], whereby a decrease was observed in VCN and IC. In the present study, an increase in
MEMRI signal intensity within the amygdala and therefore, an elevation in calcium-related
activity, might rely on similar mechanisms responsible for synaptic transmission. However,
further investigation is needed to clarify the differences in subcortical auditory structures.
One possible mechanism for this increase in calcium-related activity could be the direct
action of salicylate on neuronal and synaptic activity within those particular brain structures.
Salicylate largely influences the pre- and postsynaptic conductance of several transmembrane
ion channels by modulating neurotransmitter activity (e.g. modulation of GABA-mediated
inhibition) [38, 40]. In turn, the activation of neurons by releasing action potentials and
increasing excitatory synaptic transmission can be induced [37, 79–81]. Further, an increase in
immediate early gene activity and its possible function in upregulation of NMDA receptor
activity was demonstrated in the dorsal cochlear nucleus [41]. These mechanisms depend on
intracellular calcium and might induce calcium and manganese influx into the cell, both being
able to elicit several calcium-related neuronal responses [65, 66, 82]. This might have contrib-
uted to an elevated intracellular manganese accumulation followed by a higher MEMRI signal
intensity in the present data. This idea is supported by our recent findings of salicylate effects
in brain slices [55].
It should be mentioned that pharmacological removal of cochlear sensory cells reduces
auditory nerve input towards the central auditory system. This happens particularly when
inner hair cells have been affected (in addition to OHC damage), thereby inducing changes in
central neuronal activity (e.g. compensatory hyperactivity), as shown by several studies in this
Salicylate-Induced Changes in Brain Activity
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field. For a review, see [83]. However, hearing impaired controls as well as salicylate-treated
animal should be affected to a similar extent. Another important issue is that salicylate appli-
cation itself has the property to further diminish sensory function. It has been reported that
salicylate particularly influences outer hair cell motility and thereby significantly reduces stim-
ulus-driven auditory nerve activity [22, 46, 84, 85]. Any such effect should play only a minor
role in the present data, since spontaneous calcium-related activity was measured and animals
were kept in a quiet environment to prevent external acoustic stimulation during the experi-
ments. However, with the current experimental design, an additional salicylate-induced hear-
ing impairment and a further salicylate-driven effect on the function of surviving hair cells
could not be excluded completely and might therefore slightly contribute to the observed
effects.
The present study indicates that salicylate-induced activity changes in central auditory
brain areas, including possibly tinnitus, exist to a large extent. Since observations were made
after reduction of peripheral effects mediated by cochlear hair cells, these effects cannot be
entirely explained by salicylate’s action on peripheral tissue.
Is there a correlation with noise-induced hearing loss/tinnitus?
The present results indicate that the mechanisms through which salicylate impacts on activity
in several auditory and non-auditory brain structures appears different to those known from
noise-induced hearing loss (and possibly tinnitus generation); particularly immediately after
treatment. Acute noise-exposure is accompanied initially by cochlear changes. In a second
stage, the altered afferents are probably responsible for modulating central auditory processing.
However, permanent tonotopic and other pathophysiological changes appear to be largely
established by compensatory neuroplasticity, acting to overcome the reduced cochlear output
and damaged central auditory structures. This is in line with the finding that an increased
spontaneous firing rate (SFR) in the DCN (after 140 dB SPL noise exposure) could be recorded
only after a 2–3 days’ period [86]. Once these changes are established as autonomous nervous
activity, they seem to become uncoupled from cochlear projections and show a rebalancing of
central inhibitory and excitatory neurotransmission [87, 88]. It has been demonstrated that
sectioning of the auditory nerve and, thus, abolishing the peripheral input, had no effect at all
on the increased SFR in the DCN after noise exposure [89]. Further discrepancies between the
impact of noise and salicylate became apparent when comparing the current data with our
recent findings using the MEMRI technique. In earlier MEMRI experiments we demonstrated
that noise-induced hearing loss leads to short- and long-term changes in calcium-related activ-
ity in central auditory structures [70]. As the generation of tinnitus was not tested in both stud-
ies, differences in Ca2+ activity patterns between the two studies even indicate that hearing
impairment related to either salicylate application or noise trauma have varying impacts on
central auditory system physiology and might therefore, rely on different pathophysiological
mechanisms. This may lead to the hypothesis that the appearance of tinnitus due to salicylate
or noise is also based on different sources. Calcium-related activity patterns have also been
observed by another study investigating activity changes in several brain structures after induc-
tion of noise- or salicylate-related tinnitus using manganese-enhanced MRI [52]. Signal inten-
sity differences between noise and salicylate treatment were only present in some of the
structures investigated: e.g. the DCN and part of the inferior colliculus (DCIC). The discrepan-
cies between these studies might be related to the particular experimental design, as Holt and
colleagues used rats and their animals were normal hearing before treatment. Moreover, noise
was delivered unilaterally and was narrow-band, which is in contrast to our recent work and
could explain the different results.
Salicylate-Induced Changes in Brain Activity
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In essence, the present data support the idea that the impact of salicylate application or
noise trauma on the auditory system are probably based on different mechanisms, even if com-
parable changes of electrophysiological properties could be observed in vivo: e.g. increased SFR
in central auditory areas [47, 90, 91], alterations in synaptic transmission [9, 40, 41, 92, 93] and
an increase in neural synchrony [51, 94]. Since salicylate action is reversible, central pharmaco-
logical effects of salicylate compared to those of (permanent) noise-induced hearing
impairment and tinnitus seem to induce different pathophysiologies and might therefore, be
considered as different causes for the same symptoms.
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